ALT · Altimmune Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Market Cap
297.7M
52 Wk Range
$1.50 - $6.44
Previous Close
$1.53
Open
$1.53
Volume
4,681,210
Day Range
$1.38 - $1.53
Enterprise Value
74.7M
Cash
265.1M
Avg Qtr Burn
-37.74M
Insider Ownership
0.47%
Institutional Own.
73.64%
Qtr Updated
Sep 30th 2026
